EICHOR
● Active Not Recruiting
A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Condition: Urinary Bladder Neoplasms · Sponsor: Janssen Research & Development, LLC
About this study
The purpose of study is to compare bladder intact-event free survival (BI-EFS) in participants receiving TAR-200 in combination with intravenous (IV) cetrelimab versus concurrent chemoradiotherapy.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (290)
| Loma Linda Univ Faculty Medic | Loma Linda, California, United States | — |
| University of Southern California | Los Angeles, California, United States | — |
| Providence Saint John s Health Center | Santa Monica, California, United States | — |
| Stanford University Medical Center | Stanford, California, United States | — |
| The Urology Center of Colorado | Denver, Colorado, United States | — |
| Foothills Urology - Golden Off | Golden, Colorado, United States | — |
| Boca Raton Regional Hospital | Boca Raton, Florida, United States | — |
| Urological Research Network | Hialeah, Florida, United States | — |
| Memorial Healthcare System | Pembroke Pines, Florida, United States | — |
| Winship Cancer Institute of Emory University | Atlanta, Georgia, United States | — |
| DuPage Medical Group | Lisle, Illinois, United States | — |
| University Hospitals Seidman Cancer Center | Ann Arbor, Michigan, United States | — |
+ 278 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04658862